PVCT

Insider Trades

Name	Value	Action	Price	Current Price
Pershing EdwardDirector, Officer: CEO Disclosure amount unavailable34.9k shares BuyFeb 9, 2026 -- --

News

seekingalpha.comProvectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcriptseekingalpha.comJun 18

globenewswire.comProvectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholdersglobenewswire.comJun 8

globenewswire.comProvectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study Endglobenewswire.comMay 18

globenewswire.comBascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus's VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitisglobenewswire.comMay 4

globenewswire.comBascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitisglobenewswire.comMay 4

Trade PVCT

About Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.

CEO: Edward V. Pershing
IPO Date: Jan 15, 1997

Market Data

Open: $0.061
High: $0.062
Low: $0.061
Volume: 100.9K
Avg Volume: 181.8K
52W High: $0.105
52W Low: $0.038

Valuation

Market Cap: $26M
Enterprise Value: $29M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-3.3M
Revenue: $336k
Net Income: $-5.4M
Cash: $251k
Debt: $3.0M

Events

EarningsMay 14

actual -0.0031